Yamamura Yoshitaka, Kodera Yasuhiro, Tanemura Hiromi, Oshita Hiroo, Miyashita Kaoru, Fujimura Takashi
Dept. of Gastroenterological Surgery, Aichi Cancer Center Hospital.
Gan To Kagaku Ryoho. 2004 Mar;31(3):361-5.
The safety of chemotherapy combining TS-1 and pirarubicin (THP) for treatment of recurrent or locally advanced gastric cancer was evaluated. THP was administered by intravenous drip infusion at a dose of 14 mg/m2 every other week. TS-1 was administered orally at a dose of 40 mg/m2 twice a day for 2 weeks followed by 2 weeks of rest (level 1), for 3 weeks followed by 2 weeks of rest (level 2), and for 4 weeks followed by 2 weeks of rest (level 3). Three patients were treated with the level 1 schedule. One patient with peritoneal dissemination received 22 courses of the treatment, and benefited from a long-term NC. However the remaining 2 cases were diagnosed as PD after 4 courses and were withdrawn from further treatment. Two patients in this group suffered from grade 2 adverse events according to the NCI-CTC. Only 1 patient who had liver metastasis was treated at level 2. Fourteen courses were administered, and a PR was achieved while grade 2 adverse events were observed. One of 3 patients who were treated with level 3 had grade 3 adverse events. Consequently, 3 more cases were added to this dose level, and no additional grade 3 adverse events were observed, while grade 2 adverse events were seen in 4 cases. Urinary urgency had completely disappeared in 1 patient with peritoneal recurrence. Myelosuppression, which was the main observed adverse event, was well controlled and of brief duration. The response, including alleviation of clinical symptoms, was confirmed in 3 of 5 chemo-naive patients.
评估了替吉奥（TS-1）联合吡柔比星（THP）化疗治疗复发或局部晚期胃癌的安全性。THP通过静脉滴注给药，剂量为每两周14mg/m²。TS-1口服给药，剂量为40mg/m²，每日2次，持续2周，随后休息2周（1级），持续3周，随后休息2周（2级），持续4周，随后休息2周（3级）。3例患者接受1级方案治疗。1例腹膜播散患者接受了22个疗程的治疗，并从长期疾病稳定中获益。然而，其余2例在4个疗程后被诊断为疾病进展，退出进一步治疗。根据美国国立癌症研究所常见毒性标准（NCI-CTC），该组中有2例患者发生2级不良事件。只有1例肝转移患者接受2级治疗。共进行了14个疗程，达到部分缓解，同时观察到2级不良事件。接受3级治疗的3例患者中有1例发生3级不良事件。因此，该剂量水平又增加了3例患者，未观察到额外的3级不良事件，4例患者出现2级不良事件。1例腹膜复发患者的尿急症状完全消失。观察到的主要不良事件骨髓抑制得到了良好控制，且持续时间较短。5例初治患者中有3例确认有反应，包括临床症状缓解。
